Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, the highest since 2019, driven by a preference for smaller biotech buyouts over blockbuster mergers due to regulatory scrutiny. The ALPS Medical Breakthroughs ETF (SBIO) focuses on these mid-size biotechs, recently adding 37 companies amid a wave of trial results and takeover news. Regulatory shifts, such as the FDA's more flexible approval path for serious diseases, are also encouraging biotech investments and capital raises.
Among four Dividend Aristocrats highlighted a year ago, AbbVie and Becton Dickinson outperformed the market with strong dividend growth and solid financials, while Procter & Gamble and Brown-Forman lagged in price but maintained reliable dividend pay...
The healthcare sector has led all S&P 500 sectors with a 13.10% gain over the past three months, despite lagging year-to-date. Major pharmaceutical companies Eli Lilly, Johnson & Johnson, and AbbVie offer a mix of growth and income, with strong recen...
Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commer...
REGENXBIO reported strong Q2 2026 results, highlighted by the Phase III AFFINITY DUCHENNE trial meeting its primary endpoint and dosing the first patient in the NAAVIGATE diabetic retinopathy study. The company secured over $200 million in new capita...
